Fast-Track:Biomagnetic In-vivo Imaging of Ovarian Cancer

Information

  • Research Project
  • 7780637
  • ApplicationId
    7780637
  • Core Project Number
    R44CA123785
  • Full Project Number
    4R44CA123785-02
  • Serial Number
    123785
  • FOA Number
    PA-07-280
  • Sub Project Id
  • Project Start Date
    5/1/2008 - 16 years ago
  • Project End Date
    4/30/2011 - 13 years ago
  • Program Officer Name
    BEYLIN, DAVID M
  • Budget Start Date
    5/1/2009 - 15 years ago
  • Budget End Date
    4/30/2010 - 14 years ago
  • Fiscal Year
    2009
  • Support Year
    2
  • Suffix
  • Award Notice Date
    7/16/2009 - 15 years ago
Organizations

Fast-Track:Biomagnetic In-vivo Imaging of Ovarian Cancer

DESCRIPTION (provided by applicant): A novel method for applying nanotechnology to the early detection, localization and potential treatment of ovarian cancer has been developed. Recent measurements, using live ovarian cancer cell lines and the ovarian cancer marker CA-125, have shown that the sensitivity of this method is better than 105 cells at depths of 5 - 8 cm from the sensor. This is significantly more sensitive than the 108 cells required for ultrasound or x-ray imaging. Sensitive biomagnetic sensors are used to measure the remanence fields of superparamagnetic nanoparticles conjugated with specific markers for ovarian cancer cells or pre-cancerous lesions. Measurements indicate that 104 nanoparticles attach to each cancer cell yielding a high magnetic moment/cell. An array of SQUID sensors are used to detect and localize these superparamagnetic nanoparticles. In order to develop protocols for clinical trials, experiments are proposed using nanoparticles, labeled with several ovarian markers, injected into phantom ovaries, ovarian tissue, and extracted human ovaries. Following this, multicomponent nanoparticles, containing both marker and anti-cancer molecules will be investigated for cancer destruction using magnetic concentration. In subsequent clinical applications, labeled-magnetic nanoparticles will be injected into the patient using the procedures developed in these studies.

IC Name
NATIONAL CANCER INSTITUTE
  • Activity
    R44
  • Administering IC
    CA
  • Application Type
    4
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    371745
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    394
  • Ed Inst. Type
  • Funding ICs
    NCI:371745\
  • Funding Mechanism
    SBIR-STTR
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    SENIOR SCIENTIFIC
  • Organization Department
  • Organization DUNS
  • Organization City
    ALBUQUERQUE
  • Organization State
    NM
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    87111
  • Organization District
    UNITED STATES